Virtual screening-molecular docking-activity evaluation of Ailanthus altissima (Mill.) swingle bark in the treatment of ulcerative colitis.
Ailanthus altissima (Mill.) Swingle Bark
Evaluation
Molecular Docking
Ulcerative Colitis
Virtual screening
Journal
BMC complementary medicine and therapies
ISSN: 2662-7671
Titre abrégé: BMC Complement Med Ther
Pays: England
ID NLM: 101761232
Informations de publication
Date de publication:
15 Jun 2023
15 Jun 2023
Historique:
received:
16
11
2022
accepted:
06
05
2023
medline:
19
6
2023
pubmed:
16
6
2023
entrez:
15
6
2023
Statut:
epublish
Résumé
The dried bark of Ailanthus altissima (Mill.) Swingle is widely used in traditional Chinese medicine for the treatment of ulcerative colitis. The objective of this study was to explore the therapeutic basis of the dried bark of Ailanthus altissima (Mill.) Swingle for the treatment of ulcerative colitis based on Virtual Screening-Molecular Docking-Activity Evaluation technology. By searching the Traditional Chinese Medicine Systems Pharmacology TCMSP Database and Analysis Platform, 89 compounds were obtained from the chemical components of the dried bark of Ailanthus altissima (Mill.) Swingle. Then, after preliminarily screening the compounds based on Lipinski's rule of five and other relevant conditions, the AutoDock Vina molecular docking software was used to evaluate the affinity of the compounds to ulcerative colitis-related target proteins and their binding modes through use of the scoring function to identify the best candidate compounds. Further verification of the compound's properties was achieved through in vitro experiments. Twenty-two compounds obtained from the secondary screening were molecularly docked with ulcerative colitis-related target proteins (IL-1R, TLR, EGFR, TGFR, and Wnt) using AutoDock Vina. The free energies of the highest scoring compounds binding to the active cavity of human IL-1R, TLR, EGFR, TGFR, and Wnt proteins were - 8.7, - 8.0, - 9.2, - 7.7, and - 8.5 kcal/mol, respectively. The potential compounds, dehydrocrebanine, ailanthone, and kaempferol, were obtained through scoring function and docking mode analysis. Furthermore, the potential compound ailanthone (1, 3, and 10 µM) was found to have no significant effect on cell proliferation, though at 10 µM it reduced the level of pro-inflammatory factors caused by lipopolysaccharide. Among the active components of the dried bark of Ailanthus altissima (Mill.) Swingle, ailanthone plays a major role in its anti-inflammatory properties. The present study shows that ailanthone has advantages in cell proliferation and in inhibiting of inflammation, but further animal research is needed to confirm its pharmaceutical potential.
Sections du résumé
BACKGROUND
BACKGROUND
The dried bark of Ailanthus altissima (Mill.) Swingle is widely used in traditional Chinese medicine for the treatment of ulcerative colitis. The objective of this study was to explore the therapeutic basis of the dried bark of Ailanthus altissima (Mill.) Swingle for the treatment of ulcerative colitis based on Virtual Screening-Molecular Docking-Activity Evaluation technology.
METHODS
METHODS
By searching the Traditional Chinese Medicine Systems Pharmacology TCMSP Database and Analysis Platform, 89 compounds were obtained from the chemical components of the dried bark of Ailanthus altissima (Mill.) Swingle. Then, after preliminarily screening the compounds based on Lipinski's rule of five and other relevant conditions, the AutoDock Vina molecular docking software was used to evaluate the affinity of the compounds to ulcerative colitis-related target proteins and their binding modes through use of the scoring function to identify the best candidate compounds. Further verification of the compound's properties was achieved through in vitro experiments.
RESULTS
RESULTS
Twenty-two compounds obtained from the secondary screening were molecularly docked with ulcerative colitis-related target proteins (IL-1R, TLR, EGFR, TGFR, and Wnt) using AutoDock Vina. The free energies of the highest scoring compounds binding to the active cavity of human IL-1R, TLR, EGFR, TGFR, and Wnt proteins were - 8.7, - 8.0, - 9.2, - 7.7, and - 8.5 kcal/mol, respectively. The potential compounds, dehydrocrebanine, ailanthone, and kaempferol, were obtained through scoring function and docking mode analysis. Furthermore, the potential compound ailanthone (1, 3, and 10 µM) was found to have no significant effect on cell proliferation, though at 10 µM it reduced the level of pro-inflammatory factors caused by lipopolysaccharide.
CONCLUSION
CONCLUSIONS
Among the active components of the dried bark of Ailanthus altissima (Mill.) Swingle, ailanthone plays a major role in its anti-inflammatory properties. The present study shows that ailanthone has advantages in cell proliferation and in inhibiting of inflammation, but further animal research is needed to confirm its pharmaceutical potential.
Identifiants
pubmed: 37322476
doi: 10.1186/s12906-023-03991-0
pii: 10.1186/s12906-023-03991-0
pmc: PMC10268345
doi:
Substances chimiques
ailanthone
981-15-7
ErbB Receptors
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
197Subventions
Organisme : the Science and Technology Innovation Project of Shaanxi Province
ID : 2015SF2-08-01
Organisme : the Social Development of Shaanxi Province Key Project
ID : 2017ZDXM-SF-019, S2018-ZC-GCZXXY-SF-0005
Organisme : the Shaanxi Key Laboratory of Biomedicine
ID : 2018SZS41
Informations de copyright
© 2023. The Author(s).
Références
J Ethnopharmacol. 2022 Mar 25;286:114258
pubmed: 34271112
Lancet. 2017 Apr 29;389(10080):1756-1770
pubmed: 27914657
Planta Med. 2018 May;84(8):527-535
pubmed: 29179245
J Ethnopharmacol. 2021 Jul 15;275:114121
pubmed: 33862103
Nutrients. 2016 Sep 30;8(10):
pubmed: 27706028
J Pathol. 2016 Feb;238(3):457-69
pubmed: 26564988
BMC Health Serv Res. 2021 Aug 18;21(1):836
pubmed: 34407821
Pharm Biol. 2016 Sep;54(9):1641-8
pubmed: 26956770
Development. 2022 Jan 1;149(1):
pubmed: 34910127
Evid Based Complement Alternat Med. 2021 Apr 27;2021:5570968
pubmed: 34007291
Molecules. 2020 Sep 02;25(17):
pubmed: 32887218
Pharmacol Res. 2021 Jul;169:105613
pubmed: 33915297
Front Pharmacol. 2021 Apr 22;12:644140
pubmed: 33981227
J Med Food. 2020 Jun;23(6):584-592
pubmed: 32282259
Bioorg Med Chem Lett. 2015 Mar 1;25(5):1017-20
pubmed: 25666824
Sci Rep. 2021 Feb 18;11(1):4049
pubmed: 33603068
Comput Math Methods Med. 2021 Nov 24;2021:8323661
pubmed: 34868345
Oncol Lett. 2018 Apr;15(4):6022-6028
pubmed: 29552229
BMC Complement Altern Med. 2016 Nov 16;16(1):459
pubmed: 27846836
Front Pharmacol. 2020 Dec 10;11:603476
pubmed: 33362558
Am J Physiol Lung Cell Mol Physiol. 2003 Aug;285(2):L492-9
pubmed: 12851215
Molecules. 2016 May 16;21(5):
pubmed: 27196883
Lancet. 2020 Jan 11;395(10218):123-131
pubmed: 31929014
Curr Oncol. 2022 Aug 25;29(9):6091-6114
pubmed: 36135048
Cancer Cell Int. 2020 Nov 23;20(1):561
pubmed: 33292235
Value Health. 2017 Jun;20(6):752-761
pubmed: 28577692
Molecules. 2021 Nov 11;26(22):
pubmed: 34833900
Springerplus. 2013 Mar 18;2(1):115
pubmed: 23638404
J Biomol Struct Dyn. 2021 Apr;39(7):2302-2317
pubmed: 32299297
Molecules. 2020 Dec 25;26(1):
pubmed: 33375687
Biomed Res Int. 2017;2017:4751780
pubmed: 29147652
Front Pharmacol. 2021 May 13;12:615506
pubmed: 34093175
Biomolecules. 2019 Sep 27;9(10):
pubmed: 31569830
Front Pharmacol. 2022 Apr 14;13:854215
pubmed: 35496280
Phytother Res. 2003 Jun;17(6):675-7
pubmed: 12820239
J Crohns Colitis. 2020 May 21;14(4):508-524
pubmed: 31630153
Molecules. 2020 Dec 02;25(23):
pubmed: 33276431
Eur J Nutr. 2021 Aug;60(5):2275-2291
pubmed: 33788019
J Ethnopharmacol. 2011 Jul 14;136(3):428-35
pubmed: 20573566
World J Gastroenterol. 2014 Nov 28;20(44):16389-97
pubmed: 25469007
World J Gastroenterol. 2014 Nov 14;20(42):15899-909
pubmed: 25400476
Nutrients. 2020 May 02;12(5):
pubmed: 32370215
Front Pharmacol. 2020 Jan 20;10:1552
pubmed: 32038240
J Ethnopharmacol. 2022 May 10;289:115084
pubmed: 35134488
ACS Omega. 2021 Apr 22;6(17):11639-11649
pubmed: 34056319
J Ethnopharmacol. 2017 Feb 23;198:389-398
pubmed: 28119098
Drug Des Devel Ther. 2021 Jul 28;15:3255-3276
pubmed: 34349502
Molecules. 2021 Jun 30;26(13):
pubmed: 34209011